Who should not take Pramlintide (Symlin)?
Documented caution flags for Pramlintide (Symlin) include hypoglycemia unawareness and gastroparesis. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Pramlintide (Symlin) is limited.
Documented caution flags for Pramlintide (Symlin)
- Hypoglycemia unawareness
- Gastroparesis
- A1C > 9%
- Pregnancy / nursing
Reported side effects to weigh
- Severe hypoglycemia (when paired with insulin without dose adjustment, boxed warning)
- Nausea, vomiting
- Anorexia
- Headache
References
- Pramlintide as an adjunct to insulin therapy in T1D, review — Edelman SV et al., Diabetes Technol Ther, 2008
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets — Hollander P et al., Diabetes, Obesity & Metabolism, 2003
- Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes — Pullman J et al., Vascular Health and Risk Management, 2006
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pramlintide (Symlin)
Full Pramlintide (Symlin) breakdownPramlintide (Symlin) what it's used forPramlintide (Symlin) side effectsPramlintide (Symlin) how to take itPramlintide (Symlin) mistakes to avoidPramlintide (Symlin) half-lifePramlintide (Symlin) how long to workPramlintide (Symlin) legal statusPramlintide (Symlin) how it worksAsk the AI Coach
Last updated 2026-06-15.